ArticleFrontiers in neurology2023

SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.

Jeffrey L Bennett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.